Medical Affairs and Market Access

Real-world patients. Research-ready evidence. Faster processes.

MPIRIQ extracts patient insights from routine care and turns them into research-ready real-world evidence for studies, benefit assessments, and scientific communication.

Why this matters

Untapped patients. Unused evidence.

Most medical care happens in outpatient settings, yet a large share of this patient data remains invisible to research. MPIRIQ changes that, through AI-supported data extraction directly from routine care, de-identified, validated, and research-ready.

RWE and NIS: two application areas

Medical Affairs Support

Structured care data as the foundation for MSL work, guideline engagement, and scientific communication, directly from the German outpatient setting.

Market Access Teams

Outpatient insights as the foundation for benefit assessments, reimbursement negotiations, and payer communication, directly from the German outpatient setting.

Evidence generation from routine care.

Broad Data Access

Routine practices and patient populations that sit outside established research structures.

Validated Data Quality

Not just AI outputs: our data science team reviews and validates extracted information for credible, usable results.

Closed-Loop Study Execution

From study setup to data delivery, one process, one interface, no vendor chaos.

Why MPIRIQ

Data you can trust. Evidence you can act on.

Transparent Consent

Patients provide consent for the scientific use of their data, always voluntarily, always traceable, and with full transparency toward treating physicians and patients alike.

Ethical collaboration. Real impact.

Real-world data only creates value if it’s used responsibly. The MPIRIQ framework ensures every study serves both scientific progress and patient interests, not one at the expense of the other.

GDPR compliant by design

Every dataset is de-identified at source, inside the practice, and transmitted encrypted within a secure European cloud infrastructure. Full GDPR compliance, built in from the start.

Spritze wird aus einem Fläschchen aufgezogen
Let’s get in touch

You gain substance. The evidence becomes more credible.

Let’s talk for 30 minutes about the evidence gaps your team is facing, whether ahead of a benefit assessment, in MSL preparation, or building a broader RWE strategy.

FAQ

What sponsors want to know before deciding.

Is the data suitable for AMNOG?

That depends on the specific question and data density in your indication. For supplementary evidence in dossier contexts, routine care data is increasingly accepted.

How does this differ from statutory claims data?

Claims data shows what was billed. MPIRIQ data shows what was clinically documented, with diagnostic depth, longitudinal detail, and therapy granularity not captured in claims.

Can we bring our own research questions?

Yes. We work from your question outward. Whether prospective monitoring or retrospective analysis, the setup follows your scientific and regulatory needs.

More for life science teams